NCT04276376 (ARIANES) is a Phase 2 clinical trial of Atezolizumab in Solid Tumor, sponsored by Gustave Roussy, Cancer Campus, Grand Paris.

Who is sponsoring NCT04276376?

NCT04276376 is sponsored by Gustave Roussy, Cancer Campus, Grand Paris.

What drugs are being tested in NCT04276376?

Interventions in NCT04276376: Atezolizumab, Rucaparib.

What condition does NCT04276376 study?

NCT04276376 studies Solid Tumor.

Is NCT04276376 still recruiting?

NCT04276376 is currently terminated. Last updated 1 December 2025.

Last reviewed 2025-12-01 · How we verify

NCT04276376: ARIANES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Terminated Phase 2 Last updated 1 December 2025

What this trial tests

Phase 2 trial testing Atezolizumab in Solid Tumor in 130 participants. Terminated before completion.

Timeline

12 April 2019

Primary endpoint
25 January 2023

12 December 2023

Quick facts

Lead sponsor	Gustave Roussy, Cancer Campus, Grand Paris
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	12 April 2019
Primary completion	25 January 2023
Estimated completion	12 December 2023
Sites	1 location across France

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →
Rucaparib (RUCAPARIB) — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F, Italiano A. · · 2020 · cited 163× · PMID 32526888 · DOI 10.3390/cancers12061502
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H, Caeser R, Chavan SS, Zhan YA, et al · · 2022 · cited 91× · PMID 35584676 · DOI 10.1016/j.celrep.2022.110814
Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103
Alterations of DNA damage repair in cancer: from mechanisms to applications.
Jiang M, Jia K, Wang L, Li W, et al · · 2020 · cited 70× · PMID 33490197 · DOI 10.21037/atm-20-2920
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C, Qin K, Lin A, Jiang A, et al · · 2022 · cited 60× · PMID 36071479 · DOI 10.1186/s13046-022-02469-0
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K. · · 2022 · cited 56× · PMID 35435784 · DOI 10.1080/13543784.2022.2067527
PARP inhibitors in gastric cancer: beacon of hope.
Wang Y, Zheng K, Huang Y, Xiong H, et al · · 2021 · cited 42× · PMID 34167572 · DOI 10.1186/s13046-021-02005-6
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND, Knepper TC, Ragg S, Walko CM. · · 2021 · cited 38× · PMID 32535906 · DOI 10.1002/cpt.1946

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Gustave Roussy, Cancer Campus, Grand Paris trials

Trials by the same sponsor.

NCT07303387 — Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. · Phase 2 · not yet recruiting
NCT07159451 — A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovaria · Phase 2 · recruiting
NCT06781996 — A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuva · Phase 3 · recruiting
NCT07016230 — Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and · Phase 2 · recruiting
NCT06902883 — Study on the Effectiveness and Comfort of Innovative Solutions for the Internal Transport of Patients in Wheelchairs in · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04276376 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gustave Roussy, Cancer Campus, Grand Paris
Last refreshed: 1 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04276376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing